A review of AbobotulinumtoxinA (Dysport).

Z. Paul Lorenc; Jeffrey M. Kenkel; Steven Fagien; Haideh Hirmand; Mark S. Nestor; Anthony P. Sclafani; Jonathan M Sykes; Heidi A. Waldorf

doi:10.1177/1090820X12474632

A review of AbobotulinumtoxinA (Dysport).

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M Sykes, Heidi A. Waldorf

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.

Original language	English (US)
Journal	Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery
Volume	33
Issue number	1 Suppl
DOIs	https://doi.org/10.1177/1090820X12474632
State	Published - Mar 2013
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1177/1090820X12474632

Fingerprint Dive into the research topics of 'A review of AbobotulinumtoxinA (Dysport).'. Together they form a unique fingerprint.

Cite this

A review of AbobotulinumtoxinA (Dysport). / Lorenc, Z. Paul; Kenkel, Jeffrey M.; Fagien, Steven; Hirmand, Haideh; Nestor, Mark S.; Sclafani, Anthony P.; Sykes, Jonathan M; Waldorf, Heidi A.

In: Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery, Vol. 33, No. 1 Suppl, 03.2013.

Research output: Contribution to journal › Article › peer-review

@article{181853d22b45421d91e671fc79de05ab,

title = "A review of AbobotulinumtoxinA (Dysport).",

abstract = "AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.",

author = "Lorenc, {Z. Paul} and Kenkel, {Jeffrey M.} and Steven Fagien and Haideh Hirmand and Nestor, {Mark S.} and Sclafani, {Anthony P.} and Sykes, {Jonathan M} and Waldorf, {Heidi A.}",

year = "2013",

month = mar,

doi = "10.1177/1090820X12474632",

language = "English (US)",

volume = "33",

journal = "Aesthetic Surgery Journal",

issn = "1090-820X",

publisher = "SAGE Publications Inc.",

number = "1 Suppl",

}

TY - JOUR

T1 - A review of AbobotulinumtoxinA (Dysport).

AU - Lorenc, Z. Paul

AU - Kenkel, Jeffrey M.

AU - Fagien, Steven

AU - Hirmand, Haideh

AU - Nestor, Mark S.

AU - Sclafani, Anthony P.

AU - Sykes, Jonathan M

AU - Waldorf, Heidi A.

PY - 2013/3

Y1 - 2013/3

N2 - AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.

AB - AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.

UR - http://www.scopus.com/inward/record.url?scp=84883047499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883047499&partnerID=8YFLogxK

U2 - 10.1177/1090820X12474632

DO - 10.1177/1090820X12474632

M3 - Article

C2 - 23515194

AN - SCOPUS:84883047499

VL - 33

JO - Aesthetic Surgery Journal

JF - Aesthetic Surgery Journal

SN - 1090-820X

IS - 1 Suppl

ER -